[{"orgOrder":0,"company":"ARScience Bio","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"ARScience Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARScience Bio \/ Coya Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"ARScience Bio \/ Coya Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by ARScience Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          APGA Annual Conference
                          Not Confirmed
                          APGA Annual Conference
                          Not Confirmed

                          Details : Under the agreement with ARScience, Coya has been granted the rights to develop and commercialize COYA 301 as a monotherapy for the treatment of multiple autoimmune diseases. COYA 301 is an immunomodulatory cytokine, intended to enhance regulatory T cell...

                          Product Name : COYA 301

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          February 15, 2023

                          Lead Product(s) : COYA 301

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Coya Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank